Company ProfilePremium

Floridienne S.A.

Company Profile Analysis

Ticker: FLOB.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Floridienne S.A. - Company showcase

Year Founded & Workforce

3,425 Employees

Floridienne S.A. logo

Floridienne S.A. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Floridienne S.A. Overview

Floridienne is a family-anchored Belgian industrial holding that builds and controls leaders in niche markets. Since 2023 it has become, economically, a listed proxy for BioFirst Group, which it controls at 59.1%. BioFirst describes itself as the world's largest pure-play agricultural biologicals group. It combines Biobest (beneficial insects, bumblebee pollination and greenhouse integrated pest management) with BIOTROP (Brazil's leading microbial inoculants, biostimulants and biopesticides for open-field row crops), BioWorks (US biopesticides) and Plant Products (North American distribution).

Life Sciences generated 74% of FY2025 group turnover of €725.9m and 87% of divisional EBITDA. The Life Sciences division also includes Natix, a natural-extracts platform for enzymes, essential oils and snail extracts. Two smaller pillars complete the portfolio. Gourmet Food (€155m) makes cold sauces and gastronomic specialities for Benelux and French retail. The Chemicals/Recycling division (€32m) comprises SNAM, which recycles EV and industrial batteries in France, and Kimflor, a Turkish maker of PVC stabilisers. The investment case rests on structural substitution of synthetic agrochemicals by biologicals, set against FX exposure (USD, CAD, BRL), heavy minority interests and thin conversion of EBITDA into group-share net profit.


Company's own description

In every regulated release, Floridienne presents itself as a Belgian industrial group listed on Euronext Brussels that ranks among European or world leaders in market niches. It says its activities are concentrated in three sectors: Life Sciences, Gourmet Food and Chemicals. The FY2025 release and the H1 2026 report increasingly call the third pillar the Recycling Division (source: FY2025 results, 31 Mar 2026; H1 2026 report, 30 Sep 2026).

Independent characterisation

BusinessValue-chain positionRevenue modelCustomersEnd-markets
Biobest (BioFirst)Producer (insect rearing, bumblebee hives) plus distributor/advisorProduct sales, with technical-advisory service embeddedGreenhouse growers (vegetables, soft fruit, ornamentals), distributorsProtected horticulture: Europe, North America, Mexico, Turkey, Australia, etc.
BIOTROP (BioFirst)Biotech developer and manufacturer (fermentation of beneficial bacteria and fungi)Product sales, multi-channel (distributors, co-ops, direct)Row-crop farmers (soy, corn, cotton, sugarcane)Brazilian open-field agriculture; rollout to the US and Europe
BioWorks (BioFirst)Biopesticide developer and manufacturerProduct salesGreenhouse, ornamental and specialty-crop growersUnited States
Plant Products (BioFirst)Distributor of integrated pest management and horticultural inputsDistribution marginGreenhouse growersCanada and US
NatixExtractor and producer of natural bioactives (enzymes incl. bromelain and pancreatin, essential oils, snail slime)B2B ingredient salesNutrition, pharma, nutraceutical and cosmetics manufacturersGlobal
Food DivisionFood manufacturer (private label and brands)Product sales; highly seasonal (year-end festivities)Mass retail (Belgium, France), food service, exportPackaged food
SNAMRecycler of batteries (Li-ion, NiMH, NiCd) recovering purified metalsGate fees plus sale of recovered metals (commodity-linked)Collection schemes, OEMs, industryEuropean battery end-of-life
KimflorChemical manufacturer (Ca-Zn and heavy-metal-free PVC stabilisers)Product salesPVC pipe and fitting makersTurkish and regional construction

Floridienne is a controlled holding company with operating consolidation. It fully consolidates subsidiaries in which it often holds less than 100%, so a large and growing slice of consolidated profit belongs to minorities.

Minority equity is large: At 30 Jun 2026, non-controlling interests were €278.4m against Floridienne shareholders' equity of €399.3m.

Group-share profit is thin: FY2025 consolidated net profit was €15.1m, of which the group share was €7.9m.

The group's value chain positions are as follows.

The revenue mix is overwhelmingly product sales. There is no subscription or licensing revenue of note; some advisory services are bundled in Biobest's offering. An exact product/service split is NPD.

Strategy

Stated strategy themes (FY2025 results and H1 2026 report)

  1. Niche leadership. Hold majority positions in high-potential niche markets; the Terhormon step-up is cited explicitly as an example.

  2. Biologicals as the core growth engine. Build BioFirst into a global, full-range biologicals platform covering biocontrol, inoculants, biostimulants and pollination, across protected and open-field crops.

  3. Internationalising BIOTROP. Roll out BIOTROP's inoculants, biofertilisers and biopesticides beyond Brazil into North America and Europe. Management expects EU regulatory initiatives to speed up approval of biocontrol products and so support medium-term growth.

  4. Capacity-led organic growth. Capacity investment at BioFirst (Belgium, Brazil), Food (cold sauces from 2026) and SNAM (battery recycling volumes).

  5. Operational efficiency in Food. Withdraw unprofitable references, specialise gastronomic-speciality sites and enforce strict cost control.

  6. Structural tailwinds in Recycling. EV fleet electrification will supply end-of-life batteries, while EU rules raise targets for collection, recycling efficiency and recycled content.

Strategic initiatives, last 24 months

DateInitiativeDetail
2,024BioFirst brand architectureBiobest becomes BioFirst Group: Biobest (macrobials, pollination) and BIOTROP (microbials)
2024–2025Capacity programmesNew Biobest (Belgium) and BIOTROP (Brazil) capacity; SNAM capacity ramp 2025; Food cold-sauce lines
Oct 2024Recycling refocusSale of Vera Chimie Développements; SNAM concentrates on batteries
Apr 2025Asia-Pacific consolidationBugs for Bugs to 100%
Sep 2025Natix upstream integrationTerhormon majority secures pancreatin supply
Feb 2026Share split 1:10To improve accessibility and liquidity (rationale inferred)
Aug 2026BIOTROP North America platformBioWorks plus BIOTROP USA under one GM; revenue target above US$260m by 2034
Oct 2026BIOTROP to 100%Simplifies structure and accelerates synergy capture

Guidance and targets

FY2025 guidance: (H1 2025): results broadly in line with 2024. Actual EBITDA came in at €110.0m versus €116.8m.

FY2026 guidance: (FY2025 results): the Board expects higher results in 2026. The H1 2026 report states a positive outlook for the year as a whole.

Quantified medium-term group targets: NPD. Only the BIOTROP North America 2034 revenue target and the BioWorks US$100m target are quantified.

Products & Services

Granular SKU-level specifications, launch years and pricing are largely NPD in Floridienne's filings. The catalogue below is built from filings plus subsidiary communications.

Life Sciences — BioFirst Group

Line / brandDescriptionTarget customerNotes
Biobest — beneficial insects and mites (macrobials)Mass-reared predatory mites, parasitic wasps and predatory bugs for biological control of whitefly, thrips, spider mite, aphids, etc.Greenhouse vegetable, soft-fruit and ornamental growersCore historical business. Faced weaker pest pressure and keener North American competition in 2025–H1 2026 (H1 2026 report).
Biobest — bumblebee pollinationCommercial bumblebee hives for tomato and soft-fruit pollinationGreenhouse and tunnel growersBiobest Antalya (Turkey) is a leader in bumblebee pollination (FY2023 results).
Biobest — biopesticides and registrationsMicrobial and botanical biopesticides; regulatory registration services via Real IPM UKGrowers; distributorsReal IPM UK handles European biopesticide registrations (FY2023 results).
Biobest — monitoring and digitalPest monitoring; minority bets in Ecoation (AI crop monitoring) and Arugga (robotic pollination)Large greenhouse operatorsFinancial stakes €6.7m and €2.3m (H1 2025 report).
BIOTROP — inoculantsBacterial inoculants (e.g., nitrogen-fixing) for soybean and other row cropsBrazilian row-crop farmers, co-ops, distributorsPortfolio built on proprietary formulations and patents (FY2025 results).
BIOTROP — biostimulants and biofertilisersMicrobial biostimulants and biofertilisers for crop and soil healthRow-crop and specialty farmersRolling out in North America and Europe (FY2025 results).
BIOTROP — biopesticidesBacterial and fungal biocontrol agents for open-field pests and diseasesRow-crop farmers2026 capacity investment targets 23 million litres of beneficial bacteria and 600 t of beneficial fungi (Revista Cultivar, Oct 2026).
BIOTROP USABroad-acre biologicals for soybeans, corn, wheat, cotton and peanutsUS Corn Belt growersPart of the BIOTROP North America platform since Aug 2026
BioWorksUS biopesticides for greenhouse, ornamentals and specialty cropsUS horticultureTarget of US$100m revenue by 2034; combined BIOTROP North America target above US$260m by 2034 (HortiDaily, Aug 2026)
Plant ProductsDistribution of integrated pest management and grower inputs in Canada and the USGreenhouse growersOver €100m turnover in 2022 (FY2022 results)
Bugs for BugsAustralian producer and distributor of beneficial organismsAustralian growers100% owned since Apr 2025
Beneficial Insectary / Sierra Biologicals / AgrotechNorth American insectary; US integrated pest management distribution; Austrian distributionGrowers, distributorsAcquired 2021–2023

Life Sciences — Natix (natural extracts)

LineDescriptionEnd-market
Plant enzymes (e.g., bromelain via JV PT Bromélaine, Indonesia)Proteolytic enzymesNutrition, pharma, food processing
Animal-origin enzymes (pancreatin via Terhormon, Italy)Pancreatic enzymesPharma and nutraceutical
Essential oilsNatural aromatic extractsFlavours, fragrances, cosmetics
Snail slime extractsCosmetic bioactiveCosmetics / skincare

Food Division

LineDescriptionNotes
Cold saucesMayonnaise-type and emulsified cold sauces for retail, private label and exportGrowth engine; additional capacity commissioned from 2026; land reserve acquired for expansion (H1 2025 report)
Gastronomic specialitiesSnail-based dishes, seafood (e.g., scallops), festive productsHurt by weak French consumption in 2025; site-specialisation plan under way (FY2025 results; H1 2026 report)
Mediterranean range / spreads and saladsDips, spreads, fish saladsProduction and distribution reorganised in 2023 (FY2023 results)

Chemicals / Recycling Division

LineDescriptionNotes
SNAM — battery recyclingCollection and hydrometallurgical/pyrometallurgical recycling of Li-ion, NiMH and NiCd batteries; resale of purified metals (Ni, Co, Cd, etc.)New capacities commissioned 2025; volumes rising in H1 2026 (H1 2026 report). A battery reconditioning activity was halted in 2023 (€1.2m impairment).
Kimflor — PVC stabilisersCalcium-zinc and heavy-metal-free stabilisers for PVC pipes and fittingsTurkish market; IAS 29 hyperinflation accounting applies

Financial Narrative

Sources: Floridienne Key Figures 2023 (FY2019–FY2023); FY2023, FY2024 and FY2025 results releases. FY2021 revenue of €353.1m is as restated in the 2023 five-year table.

Income statement

Commentary. FY2022 was a step-change year: the Plant Products acquisition lifted revenue by 47% and EBITDA hit a then-record €60.4m. FY2023 was a "transition" year:

  • Biobest had a weak season (extreme weather, European growers idling heated greenhouses on energy costs, weak USD/CAD).

  • €5.9m of non-recurring BIOTROP deal costs were booked.

  • A €2.8m hyperinflation charge hit Kimflor and a €1.2m impairment hit SNAM (FY2023 results).

FY2024 was the inflection, as the first full year of BIOTROP consolidation more than doubled EBITDA to €116.8m. FY2025 showed the vulnerability of a business priced in euros but earning in USD, CAD and BRL:

  • Revenue still grew 4.1%.

  • EBITDA fell €6.8m.

  • Group-share profit halved, hit by €4.2m of Turkish hyperinflation charges, unrealised FX losses and €9.4m of purchase-price-allocation amortisation (FY2025 results).

Balance sheet

The 2025 asset split comes from the H1 2026 comparative.

Additional balance sheet detail

Goodwill plus intangibles of roughly €585m represented about 48% of total assets at end-2024 and are almost entirely BioFirst-related: €386m of goodwill sits in Life Sciences (H1 2025 segment note). Trade working capital (inventories plus receivables minus payables) was about €172m at end-2024, or 24.7% of revenue (derived).

Cash flow

FY2024 and FY2025 operating cash flow, capex and free cash flow were not captured in the releases reviewed (NPD here; see the FY2025 annual financial report of 30 Apr 2026).

Shareholder returns

Dividend paid to Floridienne shareholders: €2.94m in June 2025 for FY2024 (€3.00 gross × shares excluding treasury) (H1 2025 report, note 20).

Buybacks: none in H1 2025; small buyback transactions in Oct–Dec 2025 (treasury rose by 738 pre-split shares). No large authorisation amount was disclosed in the sources reviewed (NPD).

Ratios (derived unless stated)

Ratio notes

  • ROE for FY2021–FY2023 and payout for FY2021–FY2023 are company-reported; the rest are derived.

Current ratio: 2.04x at end-2024, 1.84x at Jun 2025 and 1.79x at end-2025. It fell to 1.30x at Jun 2026: current liabilities rose from €212.2m to €295.5m as non-current liabilities fell from €413.7m to €325.3m. This is consistent with debt maturities and the BIOTROP minority put moving into current (H1 2026 report; interpretation is the analyst's).

Interest cover (EBITDA / debt burden): about 2.8x in both H1 2025 and H1 2026. EBIT / debt burden was about 1.1x in H1 2026, which is thin.

ROIC: not computed reliably because annual EBIT and tax are not available (NPD).

Cash conversion cycle: NPD (COGS not available on a comparable basis). End-2024 inventory of €96.9m against H1 2025 annualised raw-material costs of about €322m implies roughly 110 days of inventory (rough, derived).

Interpretation. The 2023 equity raises at the BioFirst level transformed the balance sheet. Solvency jumped to 54%, but minorities became about 40% of total equity. Since then, leverage has crept back up:

  • Net debt rose from €203m (FY2023) to €303m (Jun 2026), driven by BioFirst capacity capex.

  • Net debt to FY2025 EBITDA is about 2.4x, and roughly 2.7x on Jun 2026 net debt (derived, using trailing EBITDA of about €114.5m = FY2025 €110.0m − H1 2025 €36.0m + H1 2026 €40.5m).

Profitability at group-share level is structurally low. Even record FY2024 produced only a 3.9% ROE, because:

  1. Minorities take about half of consolidated profit.

  2. Acquisition-related amortisation runs at €9–10m a year.

  3. FX and hyperinflation charges recur.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsPrincipal entities / brands

Life Sciences

Biological crop protection (macrobials and microbials), pollination, biostimulants, inoculants; natural extracts

BioFirst Group (Biobest, BIOTROP, BioWorks, Plant Products, Beneficial Insectary, Bugs for Bugs, Biobest Antalya, Real IPM, Sierra Biologicals, Agrotech); Natix (incl. Terhormon; JV PT Bromélaine, Indonesia)

Food ("Gourmet Food")

Cold sauces, gastronomic specialities (snails, seafood, Mediterranean range), spreads, salads

French and Belgian subsidiaries; Karras is named as a subsidiary with minorities.

Chemicals / Recycling

Battery recycling; PVC stabilisers

SNAM (France); Kimflor (Turkey)

Corporate

Holding services to subsidiaries; food-products trading

Floridienne S.A.

Revenue by Segment

SegmentFY2022FY2023FY2024FY2025

Life Sciences revenue (EUR Mn)

337.1359.4507.1538.3

Food revenue (EUR Mn)

135.9146.6151.0155.2

Chemicals/Recycling revenue (EUR Mn)

45.443.339.332.4

Group revenue (EUR Mn)

518.3549.3697.4725.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

SegmentFY2022FY2023FY2024FY2025

Life Sciences EBITDA (EUR Mn)

47.841.2102.395.4

Food EBITDA (EUR Mn)

6.38.111.011.1

Chemicals/Recycling EBITDA (EUR Mn)

8.19.05.35.7

Corporate EBITDA (EUR Mn)

-1.7-2.4-1.9-2.3

Group EBITDA (EUR Mn)

60.456.0116.8110.0

Results by Segment — Life Sciences net result

SegmentFY2022FY2023FY2024FY2025

Life Sciences net result (EUR Mn)

13.38.127.713.3

Food net result (EUR Mn)

1.32.24.15.4

Chemicals/Recycling net result (EUR Mn)

6.71.72.2-0.3

Corporate net result (EUR Mn)

-2.8-3.4-3.0-3.4

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2022FY2023FY2024FY2025

Life Sciences EBITDA margin (%)

14.211.520.217.7

Food EBITDA margin (%)

4.65.57.37.2

Chemicals EBITDA margin (%)

17.820.813.517.6

Life Sciences share of revenue (%)

65.065.472.774.2

Food share of revenue (%)

26.226.721.721.4

Chemicals share of revenue (%)

8.87.95.64.5

Life Sciences revenue growth YoY (%)

75.86.641.16.2

Food revenue growth YoY (%)

11.07.93.02.8

Chemicals revenue growth YoY (%)

0.0-4.6-9.2-17.6

Results by Segment (Half-Yearly)

MetricH1 2024H1 2025H1 2026

Life Sciences revenue (EUR Mn)

236.3259.5265.6

Food revenue (EUR Mn)

61.662.865.1

Chemicals/Recycling revenue (EUR Mn)

19.615.117.6

Life Sciences EBITDA (EUR Mn)

35.734.034.5

Food EBITDA (EUR Mn)

1.71.12.8

Chemicals/Recycling EBITDA (EUR Mn)

3.22.44.6

Life Sciences net result (EUR Mn)

6.8-4.41.0

Food net result (EUR Mn)

-1.2-0.9-0.1

Chemicals/Recycling net result (EUR Mn)

1.1-0.52.3

Corporate net result (EUR Mn)

-1.3-2.4-1.9

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (EUR Mn)

353.1518.3549.3697.4725.9

EBITDA (EUR Mn)

45.760.456.0116.8110.0

Consolidated net result (EUR Mn)

18.618.58.630.915.1

Net result group share (EUR Mn)

13.212.03.515.77.9

EPS basic pre-split (EUR)

13.4812.293.6216.078.11

EPS basic split-adjusted (EUR)

1.3481.2290.3621.6070.811

Gross DPS pre-split (EUR)

2.502.502.503.003.00

Gross DPS split-adjusted (EUR)

0.250.250.250.300.30

EBITDA margin (%)

12.911.710.216.715.2

Consolidated net margin (%)

5.33.61.64.42.1

Group-share net margin (%)

3.72.30.62.31.1

Income Statement

MetricH1 2024H1 2025H1 2026

Revenue (EUR Mn)

317.5337.4348.3

EBITDA (EUR Mn)

39.636.040.5

EBIT (EUR Mn)

19.613.415.5

Debt burden (EUR Mn)

-11.8-12.7-14.3

Other financial result (EUR Mn)

-0.3-9.8-1.4

Pre-tax result (EUR Mn)

8.2-9.10.4

Consolidated net result (EUR Mn)

5.3-8.21.3

Group-share net result (EUR Mn)

1.3-6.4-0.7

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (EUR Mn)

417.4608.11,262.31,221.81,244.7

Non-current assets (EUR Mn)

221.3356.6863.2831.6865.5

Current assets (EUR Mn)

196.0251.6399.1390.1379.2

Floridienne shareholders' equity (EUR Mn)

131.6161.1404.7379.3369.2

Non-controlling interests (EUR Mn)

40.356.4274.3253.8249.5

Total equity (EUR Mn)

171.9217.5678.9633.0618.8

Net financial debt excl. leases and put options (EUR Mn)

93.2193.7203.1209.5266.4

Balance Sheet (31 Dec 2024–30 Jun 2026)

Item31 Dec 202430 Jun 202530 Jun 2026

Cash and equivalents (EUR Mn)

117.390.572.0

Goodwill (EUR Mn)

415.2409.7

NPD

Other intangibles (EUR Mn)

175.0169.5

NPD

Gross financial debt incl. leases (EUR Mn)

364.2354.5

NPD

of which bank loans (EUR Mn)

264.6274.4

NPD

of which bonds (EUR Mn)

27.722.2

NPD

of which lease liabilities (EUR Mn)

37.434.8

NPD

Non-current interest-bearing debt (EUR Mn)

267.7258.7

NPD

Current interest-bearing debt (EUR Mn)

59.160.9

NPD

Inventories incl. biological (EUR Mn)

96.9114.9

NPD

Trade receivables (EUR Mn)

137.0116.2

NPD

Trade payables (EUR Mn)

61.674.3

NPD

Net financial debt (EUR Mn)

209.5229.1302.7

Total equity (EUR Mn)

633.0606.9677.8

Cash Flow

MetricFY2019FY2020FY2021FY2022FY2023

Net operating cash flow (EUR Mn)

19.532.333.531.746.7

Cash Flow (Half-Yearly)

MetricH1 2024H1 2025

Operating cash flow (EUR Mn)

21.431.4

Capex, tangible plus intangible (EUR Mn)

26.627.7

Free cash flow, OCF minus capex (EUR Mn)

-5.23.7

Acquisitions net of cash (EUR Mn)

31.17.5

Dividends paid to third parties/minorities (EUR Mn)

0.42.1

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE, group share / opening group equity (%)

11.29.12.23.92.1

ROA, consolidated net / total assets (%)

4.53.00.72.51.2

Solvency, equity / total assets (%)

41.235.853.851.849.7

Gearing, net debt / total equity (x)

0.540.890.300.330.43

Net debt / EBITDA (x)

2.043.213.631.792.42

Asset turnover, revenue / total assets (x)

0.850.850.440.570.58

Payout, gross dividend / group share (%)

18.920.868.818.737.2

Revenue by Region

RegionH1 2024H1 2025

Belgium revenue (EUR Mn)

42.844.7

Europe ex-Belgium revenue (EUR Mn)

107.4112.0

Americas revenue (EUR Mn)

152.8166.5

Other regions revenue (EUR Mn)

14.514.2

Total revenue (EUR Mn)

317.5337.4

Revenue by Region (%)

Region (%)H1 2024 share (%)H1 2025 share (%)

Belgium

13.513.2

Europe ex-Belgium

33.833.2

Americas

48.149.4

Other

4.64.2

Share Price & Returns

Reference pointPrice

30 Jun 2024

68.0 (680.0 pre-split; H1 2025 report)

30 Jun 2025

71.0 (710.0 pre-split)

31 Dec 2025

≈66.0 (derived from −9.09% YTD to €60.00)

30 Jun 2026

60.0

8 Oct 2026

60.0

Last close (mid-Oct 2026)

58.5

Valuation Snapshot

MultipleValueBasis

Market cap (EUR Mn)

≈583

9.97m shares

P/E (FY2025 group EPS €0.811)

≈72x

Distorted by FX, hyperinflation and purchase-price amortisation

EV (EUR Mn)

≈1,164

Market cap + net debt €302.7m (Jun 2026) + book non-controlling interests €278.4m

EV / EBITDA FY2025

≈10.6x

EBITDA €110.0m

EV / EBITDA trailing (H2 2025 + H1 2026)

≈10.2x

Trailing EBITDA ≈€114.5m

EV / Sales FY2025

≈1.6x

Revenue €725.9m

P/B (group equity €399.3m, Jun 2026)

≈1.46x

—

Dividend yield

≈0.5%

€0.30 / €58.50

Analyst Ratings & Targets

BrokerRatingTargetDate

KBC Securities (Guy Sips)

Accumulate

€825 pre-split (€82.5 adjusted)

Dec 2024 (Bolero)

MarketScreener consensus

Outperform (1 analyst)

€71.00 average (+21% vs €58.50)

Oct 2026

Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Gross DPS split-adjusted (EUR)

0.250.250.250.300.30

Bucket Details

BucketAmount

Bank overdrafts

19.6

Due within 1 year

46.1

Due in years 2–5

173.5

Due beyond 5 years

115.3

Total

354.5

Analyst Conclusions

Management guidance

The Board expects higher results for FY2026 (FY2025 results, 31 Mar 2026), reaffirmed as a positive outlook for the full year in the H1 2026 report. H1 2026 delivered EBITDA growth of +12.5%, with all three divisions improving. Seasonality makes H2 decisive: BIOTROP's sales peak in July–September and Food's at year-end.

Consensus

A single covering analyst (MarketScreener) rates the stock Outperform with a €71 target. Consensus revenue and EPS growth figures are NPD.

Bull case

  1. BIOTROP compounding plus 100% ownership. Best-ever H1 2026, double-digit growth in FY2025 and full ownership since Oct 2026 should lift the share of BIOTROP profit flowing to BioFirst, and so to Floridienne at 59.1%.

  2. Normalisation of non-operating drags. H1 2026 financial result improved to −€1.4m from −€9.8m and the hyperinflation charge fell to −€0.1m from −€0.9m. If FX stabilises, group-share EPS could rebound sharply from the FY2025 trough of €0.81.

  3. Optionality on BioFirst value. The "largest pure-play biologicals group" with revenue above US$580m and EBITDA margins of about 18–20% could command a premium private or IPO valuation. That would crystallise a holding discount against a group EV/EBITDA of about 10x.

Bear case

  1. Structural margin pressure at Biobest from North American competition and pest-pressure volatility. Life Sciences EBITDA fell from €102.3m to €95.4m in FY2025 and was only +€0.5m in H1 2026.

  2. Leverage and liquidity. Net debt is up €100m in 2.5 years to €303m, the current ratio is 1.30x, and the BIOTROP minority buyout (provisioned but still cash) means interest cover sits at about 2.8x EBITDA and 1.1x EBIT.

  3. Persistent low equity returns. Group-share ROE has been 2–4% since 2023, minority leakage is about 50%, and €9–10m of amortisation recurs. Thin liquidity and a 20% float limit any re-rating.

Catalysts and monitorables (next 12 months)

9M 2026 statement (~29 Nov 2026): BIOTROP's Q3 peak season and Biobest's North American trends.

FY2026 results (~31 Mar 2027): delivery of "higher results"; net debt trajectory; dividend.

BRL, USD and CAD versus EUR: the translation and transaction FX effects.

BIOTROP US/EU traction: first meaningful revenue disclosures for the North America platform.

SNAM volume ramp and metal prices;: Food margin sustainability through Q4.

Capital structure moves at BioFirst: any co-investor exit, refinancing or listing.

Larzul court ruling (Rennes);: goodwill impairment testing at year-end.

Analyst verdict

Floridienne has completed a decade-long metamorphosis from an eclectic Belgian conglomerate into what is, in substance, a listed, family-controlled vehicle for one of the world's most complete agricultural-biologicals platforms. The strategic logic is compelling. BioFirst now spans macrobials, microbials and pollination across protected and open-field crops, anchored by BIOTROP's leadership in Brazil, the most dynamic biologicals market globally. BIOTROP has delivered record performances every year since the December 2023 acquisition, and the October 2026 buyout of its remaining minorities removes a layer of profit leakage.

The financial translation of that strategy to Floridienne shareholders, however, remains disappointing. Consolidated EBITDA doubled between FY2023 and FY2024, yet group-share net profit in FY2025 (€7.9m) was below FY2021 (€13.2m). Four factors explain the gap: minority interests absorb half of earnings; acquisition amortisation weighs on the P&L; FX translation and Turkish hyperinflation recur; and interest costs rise as leverage climbs. At roughly 10x EV/EBITDA, the market is pricing the platform at a reasonable rather than demanding multiple. At more than 70x trailing EPS, investors are paying for a recovery that has only begun to show (H1 2026 group-share result still −€0.7m).

The H1 2026 margin recovery across all three divisions, together with management's "higher results" guidance, sets up a plausible FY2026 earnings rebound. The principal swing factors are BRL and USD rates, the North American greenhouse competitive environment, and capital discipline as net debt approaches 2.7x EBITDA.

On balance, the risk-reward appears modestly positive (Accumulate-equivalent), conditional on FY2026 delivering visibly higher group-share earnings and stable leverage. Absent that, the holding-company discount and minority leakage are likely to persist.


All figures in EUR and per IFRS unless otherwise stated; fiscal years end 31 December. "NPD" = not publicly disclosed in the sources reviewed. Derived figures are analyst calculations from company-reported data.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleNotes

Marc Blanpain

Chairman of the Board, Floridienne

Signs results releases as Chairman (FY2023 and FY2025). Tenure start, age and education NPD.

Gaëtan Waucquez

CEO and director, Floridienne

CEO quoted since at least 2022. Holds 3.89% (38,732 pre-split shares) and is a concert party. Prior roles, education and age NPD.

Philippe de Spoelberch

Reference shareholder (11.68% direct; linked to Beluflo per concert agreement)

Board role NPD in sources reviewed

Jean-Marc Vandoorne

CEO, BioFirst Group

Quoted on the Oct 2026 BIOTROP buyout

Jonas Hipólito

President, BIOTROP

Named in 2026

Antonio Zem

BIOTROP co-founder; sits on the BioFirst Group board

Revista Cultivar, Oct 2026

Andre Cerignoni

GM, BIOTROP North America (from Aug 2026)

Ex-Koppert US

Chris Rose

BioWorks leader (with the company since 2013)

Led the 2026 leadership transition

Major Shareholders

HolderShares (pre-split)%

Beluflo S.A.

400,00040.13

Philippe de Spoelberch

116,42811.68

Gaëtan Waucquez

38,7323.89

Subtotal — shareholders' agreement signatories

555,160

55.69

Marinvest SA

100,00010.03
—81,5248.18

BM Albatros

37,5003.76

Floridienne (treasury)

17,3631.74

Other / free float

205,31020.60

Total

996,857

100.00

Competitive Landscape

Competitors by Segment

SegmentCompetitorType / HQPositioning vs. Floridienne

Greenhouse biocontrol and pollination

Koppert

Private, Netherlands

Global #1/#2 in macrobials and bumblebees; main rival to Biobest, including in North America

Greenhouse biocontrol

Bioline AgroSciences (InVivo group)

France/UK

Macrobial producer in Europe and the Americas

Greenhouse biocontrol

Andermatt Group

Private, Switzerland

Biocontrol (viruses, macrobials), global distribution

Biopesticides (US)

Certis Biologicals (Mitsui)

USA/Japan

US biopesticides; competes with BioWorks

Biologicals (majors)

BASF, Syngenta Biologicals, Bayer, Corteva Biologicals (Stoller, Symborg)

Global agrochemical majors

Scale, channel power; increasingly acquisitive in biologicals

Microbials / inoculants

Novonesis (Novozymes + Chr. Hansen)

Listed, Denmark

Microbial technology leader

Microbials / inoculants

Lallemand Plant Care

Private, Canada

Inoculants and biostimulants

Brazil biologicals

Koppert do Brasil, Solubio, Grupo Vittia, Simbiose, Agrivalle, UPL (NPP)

Brazil / global

Direct BIOTROP competitors; on-farm production is a further competitive threat

Natural enzymes / extracts

Enzyme producers (e.g., Enzybel peers, Asian bromelain producers) and pancreatin makers

Various

Fragmented niche

Food (cold sauces, specialities)

Private-label sauce makers; French gastronomy players (incl. Larzul)

Various

Fragmented, retailer-dominated

Battery recycling

Umicore, Fortum, Hydrovolt, Accurec, Eramet/Suez initiatives

Europe

Larger-scale rivals in EV battery recycling

PVC stabilisers

Baerlocher, Reagens, Songwon, Turkish local producers

Global / Turkey

Larger global players; Kimflor is a regional niche player

Peer Comparison FY2025

MetricFloridienne (FY2025)KoppertCertis Biologicals

Revenue

€725.9m group; €538.3m Life Sciences

—

NPD

Revenue growth

+4.1% group; +6.1% Life Sciences

NPD

NPD

EBITDA margin

15.2% group; 17.7% Life Sciences

NPD

NPD

R&D intensity

NPD

NPD

NPD

Company Snapshot

$818.4M

Revenue

3,425

Employees

Waterloo, Belgium

Headquarters

SWOT Analysis

Strengths

  • Platform scale in biologicals: Life Sciences revenue of €538.3m in FY2025, up from €191.7m in FY2021 (FY2021 and FY2025 results).
  • BIOTROP growth engine: record years in 2024 and 2025, double-digit revenue and profitability growth in FY2025, and its best-ever H1 in 2026 (FY2025 results; H1 2026 report).
  • Diversified, well-capitalised shareholder base at BioFirst: €464m of equity raised in 2023 alone (€98.5m + €365.7m) from Sofina, Tikehau and others (FY2023 results).
  • Stable family control: a 55.69% concert enables long-term capital allocation without activist pressure (H1 2025 report).
  • Food cash generation and margin repair: EBITDA up from €6.3m (FY2022) to €11.1m (FY2025); H1 2026 EBITDA more than doubled to €2.8m.
  • Liquidity buffer: cash of €72m at Jun 2026 and €117m at end-2024 (H1 2026 and H1 2025 reports).

Weaknesses

  • Minority leakage: group share is only 52% of consolidated net profit in FY2025 (€7.9m of €15.1m); non-controlling interests total €278m.
  • Low returns: group-share ROE of 2.1% in FY2025 (derived) against a cost of equity well above that.
  • Acquisition amortisation drag: €9.4m of purchase-price-allocation amortisation in FY2025 (FY2025 results).
  • Rising leverage: net debt up from €203m (FY2023) to €303m (Jun 2026); the current ratio fell to 1.30x.
  • Thin liquidity: free float of about 20%, with low volumes flagged by KBC Securities.
  • Recycling sub-scale: €32.4m revenue and a €0.3m net loss in FY2025.

Opportunities

  • BIOTROP internationalisation: the North America target exceeds US$260m by 2034 (HortiDaily, Aug 2026).
  • 100% BIOTROP ownership (Oct 2026): removes minority leakage at BIOTROP level and simplifies the structure.
  • EU regulatory acceleration for biocontrol approvals (FY2025 results outlook).
  • Fossil-energy shock: biologicals' cost base is less tied to oil and gas than synthetic chemistry (FY2025 post-balance-sheet note).
  • Battery recycling volumes: new SNAM capacity and EU recycled-content mandates (H1 2026 report).
  • Cold-sauce capacity from 2026 to meet demand across all markets (FY2025 results).

Threats

  • North American greenhouse competition compressing Biobest margins (H1 2025 and H1 2026 reports).
  • FX: H1 2025 other financial result of −€9.8m, mostly unrealised FX losses; translation hit of −€16.5m to equity in H1 2025.
  • Turkish hyperinflation: €4.2m charge in FY2025 (FY2025 results).
  • Brazilian farm-economy stress: costly inputs and lacklustre crop prices (H1 2026 report).
  • Commodity prices for purified metals (FY2023–FY2025 results).
  • Larzul litigation and investment carrying value of €2.6m plus a €0.8m receivable (H1 2025 report).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
11 Apr 2025BioFirst becomes sole owner of Bugs for Bugs (Australia)Asia-Pacific consolidation; price pre-provisioned
30 Apr 2025FY2024 annual financial report publishedAnnual filing
2 Jun 2025Q1 2025 statementQuarterly trading update
3 Jun 2025AGM approves €3.00 gross dividend (FY2024), total €2.94mDividend raised from €2.50
Jun 2025Filings on transparency/governance (23 Jun)Routine
30 Sep 2025H1 2025 report: revenue +6.3% to €337.4m; EBITDA −9.1% to €36.0m; net −€8.2m on FX lossesProfit warning in substance; FY2025 guided "broadly in line" with FY2024
30 Sep 2025North American greenhouse competition flagged as a headwind for BiobestStructural concern for the historic franchise
9 Sep 2025Natix takes majority control of TerhormonNatural-enzyme supply security
16 Oct 2025Proxy materials for a shareholder meetingPreceded the share split
Oct–Dec 2025Series of own-share transactions (≈10 filings)Small buyback activity
27 Nov 2025Voting results and voting-rights announcementShareholder approvals (split-related)
28 Nov 20259M 2025 statement: trends in line; BIOTROP outstanding; Biobest improved in Q3Reassurance after weak H1
16 Dec 2025Shareholder meeting informationCorporate action
Feb 20261-for-10 share split effective (6 or 11 Feb per differing sources)Liquidity
31 Mar 2026FY2025 results: revenue €725.9m (+4.1%), EBITDA €110.0m (−5.8%), group net €7.9m (−50%)FX and hyperinflation drag; FY2026 guided up
31 Mar 2026Middle East conflict (Iran) noted as a post-balance-sheet risk: oil, gas and logistics costsManagement argues biologicals become more competitive versus fossil-based chemistry
30 Apr 2026FY2025 annual financial report publishedAnnual filing
2 Jun 2026AGM; €0.30 gross dividend (post-split) payable 17 Jul 2026Dividend flat on a split-adjusted basis
2026 (H1)BioWorks leadership transition; Jonas Hipólito named BIOTROP PresidentManagement renewal in microbials
Aug 2026BIOTROP North America platform; Andre Cerignoni appointed GMUS growth push; 2034 targets
30 Sep 2026H1 2026: revenue €348.3m (+3.2%); EBITDA €40.5m (+12.5%); net €1.3m; group −€0.7mMargin recovery in all divisions
30 Sep 2026BIOTROP posts the best H1 in its history despite cautious Brazilian farmersConfirms the growth engine
30 Sep 2026Biobest affected by lower pest pressure and North American competition; Natix down on order phasingMixed Life Sciences picture
30 Sep 2026Net debt rises to €302.7m; equity up €58.9m on BRL strength and put-option revaluationLeverage creeping up
30 Sep 2026SNAM profitability recovering on higher volumes and better metal pricesRecycling turnaround
30 Sep 2026Food EBITDA up €1.7m on cost control and lower ingredient pricesFood margin repair
~5 Oct 2026BioFirst acquires the remaining 14.71% of BIOTROP and reaches 100%Removes minority leakage at BIOTROP level
Oct 2026Share at ~€58.5–60 (−9% YTD)Market unconvinced by the H1 recovery
29 Nov 2026 (expected)9M 2026 statementNext catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Revenue by Segment: Life Sciences revenue rose from EUR 337.1 Mn in FY2022 to EUR 538.3 Mn in FY2025.
Floridienne S.A. — Revenue by Segment
Series (EUR Mn)FY2022FY2023FY2024FY2025
Life Sciences revenue337.1359.4507.1538.3
Food revenue135.9146.6151155.2
Chemicals/Recycling revenue45.443.339.332.4
Group revenue518.3549.3697.4725.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.